Adverse Pregnancy Outcomes With Isoniazid Preventive Therapy in HIV

Date: 03/09/2018

Publication:

Infectious Disease Advisor

Isoniazid preventive therapy (IPT) for tuberculosis in pregnant women with HIV was associated with excess adverse pregnancy outcomes and may warrant a reassessment of the current World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) guidelines, according to a poster presented at CROI 2018, held from March 4-7 in Boston, Massachusetts.

Access Full Article

Clinical Trials

A5322: Long-Term Follow-up of Older HIV-infected Adults in...

The A5322 protocol is a long-term observational study, with a planned series of analyses of data to be collected from an...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

A5324: A Randomized, Double-Blinded, Placebo-Controlled...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Read More

A5346: Sitagliptin for Reducing Inflammation and Immune...

The purpose of the study is to evaluate whether sitagliptin (Januvia is the brand name for sitagliptin)...

Read More